和誉-B（Abbisko Therapeutics）今日宣布，其创新药物Pimicotinib针对腱鞘巨细胞瘤（TGCT）的新药申请（NDA）已获得美国食品药品监督管理局（FDA）正式受理。这一关键进展标志着Pimicotinib在全球化开发与商业化进程中迈出重要一步，为TGCT患者带来新的治疗希望。
和誉-B（Abbisko Therapeutics）今日宣布，其创新药物Pimicotinib针对腱鞘巨细胞瘤（TGCT）的新药申请（NDA）已获得美国食品药品监督管理局（FDA）正式受理。这一关键进展标志着Pimicotinib在全球化开发与商业化进程中迈出重要一步，为TGCT患者带来新的治疗希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.